Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $54.22M |
| Net Income (Most Recent Fiscal Year) | $-57.89M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.01 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.14 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -106.77% |
| Net Margin (Trailing 12 Months) | -106.77% |
| Return on Equity (Trailing 12 Months) | -271.88% |
| Return on Assets (Trailing 12 Months) | -42.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.38 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 4.07 |
| Inventory Turnover (Trailing 12 Months) | 3.75 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 23.95M |
| Free Float | 18.66M |
| Market Capitalization | $54.60M |
| Average Volume (Last 20 Days) | 0.09M |
| Beta (Past 60 Months) | 0.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 19.02% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |